Immunis Biomedical
Irvine, US · 4 known investors
Immunis Biomedical develops multi-active biologics based on stem cell-derived secretomes — cell-free therapeutics containing proteins, lipids and growth factors — aimed at treating age-related and immune-related diseases. Its approach targets multiple biological pathways at once rather than a single protein or mechanism.
Founders & leadership
GN
Gabriel NistorNamed on SEC filing
Board
TK
Takahide KodaBoard director
DK
Daniel KraftBoard director
HK
Hans KeirsteadChairman of the Board
Investors · 4
Funding
SEC filings, press & company announcements$32.4M disclosed across 2 of 3 rounds · 2022–2026
- Undisclosed amountSeries A First ClosingAug 2022
Remiges Ventures (lead)
Source ↗
▶$12MraisedJun 2026 · 12 investors · BiotechnologyRule 506(b)
▶$12MraisedJun 2026 · 12 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Takahide KodaDirector
- Hans KeirsteadExecutive Officer, Director
- Daniel KraftDirector
- Gabriel NistorExecutive Officer
- Offering amount
- $12M
- Amount sold
- $12M
- Minimum investment
- $50K
- First sale
- May 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$20.4MraisedOct 2024 · 27 investors · BiotechnologyRule 506(b)
▶$20.4MraisedOct 2024 · 27 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Gabriel NistorExecutive Officer
- Takahide KodaDirector
- Hans KeirsteadExecutive Officer, Director
- Daniel KraftDirector
- Offering amount
- $25M
- Amount sold
- $20.4M
- First sale
- Jun 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Immunis Biomedical do?
- Immunis Biomedical develops multi-active biologics based on stem cell-derived secretomes — cell-free therapeutics containing proteins, lipids and growth factors — aimed at treating age-related and immune-related diseases. Its approach targets multiple biological pathways at once rather than a single protein or mechanism.
- Who are Immunis Biomedical's investors?
- Immunis Biomedical's investors include Bold Capital Partners, JLS, quadraScope Venture Fund, Remiges Ventures, Inc..
- How much funding has Immunis Biomedical raised?
- Immunis Biomedical has disclosed $32.4M raised across 2 of its 3 known rounds.
- Where is Immunis Biomedical headquartered?
- Immunis Biomedical is headquartered in Irvine, US.